Gcms Attempt To Download Method To Gc Failed
Keiko Bludworth
I have a 7820A GC connected to a 5977B MS. When I submit a sample, it injects and runs as normal at first. Near the end of the run, an error message pops up that reads "Attempt to download method to GC failed." Additionally, when I check the logbook, there is an error message about vacuum system fault. I am confused by this since the sample was running fine and the pressure was being kept at the correct level by the vacuum.
Problem:
Check "Data Analysis" when running a method with 7693A injector, the following message appears after the data was acquired:"Opening data file failed with error - File not found: D:\MassHunter\GCMS\1\Data\GC105_001.d\AcqData\Devices.xml"
Problem:
While running a sequence with a method which collects the ms signal as well as the GC's FID signal. The GC-QQQ was configured to the back inlet. Was unable to tune because of an error stating, Error in Autotune! Check Abundance failed." At the end of the sequence, an unexpected program termination error and intrument control closed. There was also an error message which was presented on the status line.
Problem:
Have a valid method loaded in Drug Mode, ran a simulted batch.Then attempted to load another method that brought up Method Resolution. The method resolution panel had no Cancel button . This does not occur all the time.
Problem:
Had a liquid script method loaded. Replace the tool with a HS. Without loading a new method, attempted to run the liquid script method. It brought up a method resolution panel which one is able to cancel. The PAL3 posted a message to the logbook :error while validating script" however MassHunter GCMS Acquisition just went into pre-run and sat there until the run has been stopped manually.
Problem:
Had the liquid tool installed with a 10 uL syrings such that the sample volume was 0 - 10. In the method, set the sample volume to 1 uL. Set up a sequence using that method and attempted to override the injection volume by entering values in the Vol colume that are valid (ie. 2 uL, 3 uL and 4 uL). Saved the sequence and attempted to run it. It runs a simulation first to determine that all of the values are valid and it states the injection volume is out of range. It will not let the sequence run until the vol from the field is removed.
When metabolites of nandrolone, boldenone or formestane are found at low concentrations in doping control tests, a further CIRMS-based analysis is compulsory in order to be sure that steroid misuse has occurred. For each analyte, the factors that could generate such findings are diffrent, but in all cases the urinary concentrations always range between 1 and 20 ng/mL. Due to the low concentration of the analytes and the small contribution of 13C to the analyte molecule, an important level of selectivity and sensitivity is necessary to characterize a 13C difference. Therefore, the sample must be submitted to a long time-consuming sample preparation method.
Nevertheless, to improve detection capabilities, some laboratories include a standalone clean-up step based on the use of high performance liquid chromatography (HPLC). The present project attempts to attain these objectives by means of on-line coupling of liquid chromatography and gas chromatography (LC-GC) using the TOTAD interface, developed and patented by the UCLM research group. This analytical methodology allows the complete LC fraction containing the analytes to be transferred to the GC and, moreover, provides a better signal/noise ratio because it provides cleaner extract. These aspects, will presumably improve sensitivity by one or two orders of magnitude. The project will focus on developing an analytical method in which the hydrolysed extract is derivatised (off-line) and analysed by LC-GC. Two different detectors will be used, leading to LC-GC-MS and/or LC-GC-C-IRMS coupling. Automation of the system by using an autosampler will also be attempted. The objective of the present project is to develop a sensitive, automatic, robust and reliable analytical method to be used for the analysis of the mentioned steroids in urine. The method should allow the detection limits required to be reached, thereby providing a powerful tool for the efficient control of the misuse of anabolic steroids.
It has been developed a sensitive, automatic, robust and reliable method for analyzing steroid in a urine using on line coupled LC-GC-C-IRMS (liquid chromatography-gas chromatography-combustion isotope ratio mass spectrometry) with the TOTAD (Through iven Transfer Adsorption Desorption) interface to discriminate between the endogenous or exogenous origin of the same, and by on-line coupled LC-GC-MS to confirm the purity and the identity of the steroid peaks. Urine samples spiked at 5 ng/mL or 10 ng/mL with the steroid to be analysed were used. Of each urine sample 20 mL was hydrolyzed, extracted, purified by a first RPLC step of un-derivatized steroids, derivatized to acetylsteroids and, finally, submitted to on-line LC-GC with CIRMS or MS detection. In the coupled system a second RPLC cleaning of derivatized steroids is applied, and the l!...C fractions containing the analytes are completely transferred to GC-CIRMS or GC-MS.
l!...C-GC-CIRMS methods were devefoped for the analysis of 19-Norandrosterone (19-NA) and for Bodenone (Bo) and its main metabolite (BoM). The method failed in the case of 19-NA due to an interfering compound. The derivatization of
Formestane (F) did not work properly. so that the developed method is not applicable to F analysis. In the case of Bo and BoM the method was developed successfully. The volumes of the fractions transferred from LC to GC through a fraction collector were 1000 and 900 ftL, respectively. 138Cyp08 corrected values for Bo and BoM, as well as the /:J.8 in relation to the reference compound Pregnandiol (PD), clearly indicated the exogenous origin of the steroids. The Standard Deviations of the 138CVPoB values ranged from 0.85 to 1.11 for the entire method. A confirmatory on-line LC-GC-MS analytical method was developed for Bo and BoM. Relative Standard Deviations of the absolute peak areas were below 8%, except when Bo was spiked at 10 ng/L. Detection Limits were 0.5 ng/mL for Bo and 0.05 ng/mL for BoM in full scan. When 3 ions were selected, detection limits were 0.07 and 0.008 ng/mL respectively.
For the first time, an analytical method involving the coupling of LC-GC with CIRMS has been developed. The presented methods permit the origin of urinary Bo and BoM to be identified as endogenous or exogenous. The sensitivity is substantially improved compared with currently used methods, allowing the detection limits set by WADA to be attained. The advantages of LC-CG coupling open uo the possibility of extending the methodology to other steroids and to other compounds currently analysed by GC. The high sensitivity achieved should permit the amount of the urine necessary for such analyses to be decreased. The LC-GC-C-IRMS method developed for the analysis of Boldenone has been published. Presumably, the LC-GC-MS method for the analysis of boldenone will be published shortly.
(b)(1) The collector shall pay careful attention to the donor during the entire collection process, except as provided in 26.109(b)(1), to observe any conduct that indicates an attempt to subvert the testing process (e.g., tampering with a specimen; having a substitute urine specimen in plain view; attempting to bring an adulterant, urine substitute, heating element, and/or temperature measurement device into the room, stall, or private area used for urination). If any such conduct is detected, the collector shall document a description of the conduct on the Federal CCF or through another documentation method consistent with the collection procedures of the licensee or other entity, and contact FFD program management to determine whether a directly observed collection is required, as described in 26.115.
Valsartan products, commonly used to treat high blood pressure and heart failure, have been recalled in many countries due to the presence of an impurity, N-nitrosodimethylamine (NDMA), in the recalled products. We present and evaluate a GC-MS-based analytical method for the determination of NDMA levels and attempt an investigation of NDMA concentrations in valsartan drug substances and associated products. The limit of detection and limit of quantification for the method were estimated to be 0.1 and 0.5 µg/g, respectively, when testing a 0.5-g sample. A good trueness (99%) with a small relative standard deviation (1.9%) was obtained for a valsartan product spiked with NDMA at a concentration of 1.0 µg/g. Additionally, a valsartan drug substance and the associated product, which were previously determined to have NDMA contamination, were analyzed by the method. The NDMA content by our method was very close to previously determined values. Finally, six samples, including valsartan drug substances and associated, commercially available products in Japan, all of which were derived from the company implicated in the NDMA contamination, were analyzed by our method, revealing that none of these samples contained detectable concentrations of NDMA. Overall, the data indicate that the present method is reliable and useful for determination of NDMA in valsartan drug substances and associated products.
Urine drug screening can enhance workplace safety, monitor medication compliance, and detect drug abuse. Ordering and interpreting these tests requires an understanding of testing modalities, detection times for specific drugs, and common explanations for false-positive and false-negative results. Employment screening, federal regulations, unusual patient behavior, and risk patterns may prompt urine drug screening. Compliance testing may be necessary for patients taking controlled substances. Standard immunoassay testing is fast, inexpensive, and the preferred initial test for urine drug screening. This method reliably detects morphine, codeine, and heroin; however, it often does not detect other opioids such as hydrocodone, oxycodone, methadone, fentanyl, buprenorphine, and tramadol. Unexpected positive test results should be confirmed with gas chromatography/mass spectrometry or high-performance liquid chromatography. A positive test result reflects use of the drug within the previous one to three days, although marijuana can be detected in the system for a longer period of time. Careful attention to urine collection methods can identify some attempts by patients to produce false-negative test results.
35fe9a5643